Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication "Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen".
Clinical Benefit
| Substantial |
The actual benefit of XELODA is substantial. |
Clinical Added Value
| no clinical added value |
Given the lack of data showing Xeloda to be superior to 5-fluorouracil, the Committee i considers that Xeloda does not provides IAB versus this comparator. |
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
u8Uf0XT2Jjs2AWz5
